Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/25/2009

Conference Call Scheduled for February 26, 2009 at 10:00 a.m. EST

EAST BRUNSWICK, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three months and year ended December 31, 2008. For the fourth quarter of 2008, the Company had a net loss of $24.2 million, or $0.45 per share, on total revenues of $1.1 million. For the year ended December 31, 2008, the Company had a net loss of $84.2 million, or $1.57 per share, on total revenues of $3.2 million. The Company ended the year with $78.6 million in cash and short-term investments.

Operational Highlights:

  • Submitted KRYSTEXXA(TM) (pegloticase) Biologics License Application (BLA) to the Food and Drug Administration (FDA) in October 2008.
  • FDA agreed to file our BLA application and granted a priority review at the end of December 2008.
  • Received approval of the pegloticase trade name KRYSTEXXA from both the FDA and European Medicines Agency (EMEA).
  • Amendments designed to strengthen and clarify the KRYSTEXXA BLA were filed and deemed a major amendment by the FDA. Under the Prescription Drug User Fee Act (PDUFA) regulations, the FDA extended the review period by three months beyond the original April 30, 2009 PDUFA action date.

"We finished both the fourth quarter and the year 2008 within our financial expectations while achieving several significant regulatory milestones," stated Paul Hamelin, President of Savient. "We continue to execute our business plan while being prudent with the management of our operating expenses. We have sufficient cash on hand to fund our ongoing operations for at least the next twelve months. Clearly, the last quarter has been a pivotal one for the Co
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
4. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
5. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
6. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
7. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
8. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
11. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... Gadolinium based contrast agents, frequently used during computed tomography (CT) ... associated with a very low rate of adverse effects, according ... of the American Journal of Roentgenology ( AJR ... Rochester, MN, included a total of 456,930 contrast doses administered. ...
... NASHVILLE, Tenn., Sept. 21 The bump on his ... out of surgical specialty training, craniofacial and maxillofacial surgeon Dr. Stephen ... hospital. Then came the biopsy results: the little nuisance was in ... After the first round of surgical procedures, Cantrell enrolled in a ...
... , Second Annual Event Promotes ... WASHINGTON, Sept. 20 Secretary of Veterans Affairs Eric K. Shinseki offered ... of the 2nd National Veterans Summer Sports Clinic in San Diego. ... Shinseki kicked-off the clinic by telling his personal story of dealing with ...
... let their legs move, bear weight without brain signals ... approach to treating spinal cord injuries allowed paralyzed rats ... report. , Spinal cord injuries result in paralysis when ... the brain are damaged or severed. Much of the ...
... NEW ORLEANS, Sept. 20 Jack Mackenroth, from the hit ... 20th annual NO/AIDS Walk and is bringing Living Positive By ... city. On Sunday, September 20th, Jack will participate in the Walk ... several other AIDS Service Organizations in Louisiana each year. The ...
... ... treatment program in the U.S., reNEW MAN (renewman.com) is promoting its national network of ... and older, the company helps connect professional men that exhibit signs of low testosterone ... safe-individualized treatments. , ...
Cached Medicine News:Health News:Surgeon Battling Own Cancer Developed New Treatment 2Health News:Surgeon Battling Own Cancer Developed New Treatment 3Health News:Secretary Shinseki Kicks-Off National Sports Clinic 2Health News:Paralyzed Rats Walk Again 2Health News:Paralyzed Rats Walk Again 3Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 2Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 2Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 4
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
(Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Newly-Identified K-Ras Mutated Oncogene Population in Patients with ... in Advanced Breast and ... Ovarian Cancers, ... ) today announced an expanded Phase 2 development,plan for NKTR-102 (PEG-irinotecan). ...
... Annual Meeting - - Conference call to be hosted Wednesday, June ... ... BRANFORD, Conn., June 1 CuraGen Corporation,(Nasdaq: CRGN ) today presented ... of unresectable Stage III or,Stage IV melanoma. The results were presented by ...
Cached Medicine Technology:Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 2Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 3Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 4Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 2CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 3CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 6
... The Alaris System integrates drug ... practice guidelines,into a single, modular platform. ... or remove modules as you,need them, ... the bedside,to a minimum while managing ...
... Eraser instruments have been designed to ... right tool for situations requiring precise ... of 25 gauge intraocular, bipolar, diathermy ... of target tissues for fine-tip hemostasis ...
... steps any hospital or health system can ... most effective tools available for physicians and ... documentation and electronic medical record (EMR) system, ... goal. In fact, its the most reliable ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products: